Problem We Are Solving

  • The ongoing COVID pandemic identified a need for vaccines but also antiviral therapeutics.

    • COVID Sanatio modular platform therapeutic 2020 anti-viral

  • The worldwide need for therapeutics to combat acute COVID disease will remain even after the first vaccines arrive; and regardless of their success.

  • Therapeutics will remain critical weapons in our arsenal against COVID disease that too often leads to lethal outcome.

  • The target disease states for Sanatio BioScience therapeutics are:

    Phase 1: Anti-Viral (COVID, SARS, MERS), Influenza, Ebola, and potential new viruses or strains that appear in the future

    Phase 2: Cancer-specific cell products

1. Covid-19 virus particles enter the cell and deposit their RNA
2. Covid 19 RNA encodes/makes more virus proteins
3. Covid-19 RNA makes more Covid-19 RNA for genetic material
4. Covid-19 proteins and new RNA genetic material are then packaged to make more viruses that escape from the cell and infect its neighbors.

What Do We Propose?

Design inputs: Anti-COVID therapeutic for 2020 – Platform 1

  • Tissue targeting, cell specificity modules

  • Virus specificity is readily adapted to meet virus mutation, even different virus threats
  • Therapeutic specificity is readily altered to meet virus change that can occur geographically or over time (next year’s virus strain).

Sanatio Solution

  • We send our therapeutic into cells to bind the target virus then destroy with antiviral activity
  • The cell specificity and combination of viral targeting mechanisms are novel versus other approaches
  • The modular components include modules for cell access, cell specificity, virus targeting, and anti-viral activity.

Three versions of our therapeutic:

  • Therapy 1 – Uses native, endogenous anti-viral activity
  • Therapy 2 – Adds in our externally made anti-viral module.
  • Therapy 3 – Similar to Therapy 2 with a different anti-viral component

Platform Modular Therapeutic Design

PLATFORM 1

Anti-viral modular therapeutics

1. COVID (test case target development)
2. Influenza, MERS, SARS, new threats/strains

PLATFORM 2

Individualized anti-cancer modular therapeutics Supercharged for specificity and activity (patent protected)

Sanatio is led by a team of seasoned executives and scientists.
Our solution is protected by broad IP (patent pending)

Solution Elements

Therapeutic 1: Targeting and cell penetration modules that recruit anti-viral activity from patient and ready-to-go for cell culture/animal live virus testing expected completion in Q4, 2021.

Therapeutic 2/3: Targeting, cell penetration, and anti-viral enzymatic activity modules as part of design (externally introduced anti-viral activity) Cell culture, animal testing 16 weeks

3 Basic Steps
• Build modular therapeutic–manufactured with existing standard technology
• Assemble compounds
• Testing in COVID cell culture, animal models

Timeline:
• Rapid ready-to-go design: animal live virus testing in 10 weeks: safety and efficacy

Timeline

Our Mission

Sanatio BioScience is a platform-based company built on our innovative modular therapeutics design to target and de-activate viruses or rogue cell products in cancers. Our proprietary patent-pending modular system uses biologic components in tandem arrays that focus targeting to specific cell-types and tissues and then, enhance the natural anti-viral activities within cells. Focused targeting of anti-viral activity stops the life cycle of the virus and prevents replication preferentially in infected cells and tissues.

The modular system allows us to rapidly adapt our design to target viruses (current and future). Near term focus on COVID with secondary on next threats/strains such as MERS, SARS, and Influenza by targeting the appropriate virus-specific product in infected cells and tissues. The modular approach gives Sanatio diverse avenues of therapeutic design for multiple diseases and development pathways derived from our unified modular biologic design.

Our solution is an anti-viral, therefore is targeted to infected patients. Vaccines are focused on creating immune response in noninfected population. There is synergy to have both anti-viral and vaccine solutions to combat any outbreak such as COVID. Antivirals keep the virus from spreading and patients from dying. Our anti-viral therapy will always be more quickly adapted than vaccines due to the complex nature of vaccine development and vaccination logistics globally. Therefore, large opportunity exists regardless of success of vaccines.

By the same mechanism we are also to reconfigure our therapeutic to target ‘rogue’ tumor-specific products in cancer cells. In Phase 2, anti-cancer modular designs can also be deployed in conjunction with other modes of anti-cancer treatments, for synergistic action. In this way, can decrease dosage of agents used in combination to increase safety and at the same time increase efficacy, and expand the market for Sanatio

Leadership Team

Judson Boothe, MBA

CEO, Co-founder

Judson Boothe (BSME, MBA) is a proven change agent and senior leader. Currently President of the Health division of Strax and CEO of Sanatio BioScience. Previously served as SVP of Supply Chain and VP of Business Transformation for Avanos Medical. Judson has spent his 28 year career with Kimberly-Clark, Avanos Medical, and Halyard Health in multiple roles spanning global supply chain, manufacturing, venture board seat, P&L management, marketing, field sales leadership, and most recently large-scale business transformation.

Peter Frederikse, PhD

Chief Research & Development, Co-founder

Peter Frederikse had the lead role in the design of our therapeutics and IP. He has been a molecular biologist for thirty years. Dr. Frederikse received his BS from University of Washington in Seattle, and PhD from the University of Maryland. He went on to post-doctoral studies as a New York Heart Association fellow at Columbia University in New York City. He became a Senior Scientist and at the NIH in Bethesda MD before becoming Associate Professor at Rutgers Behavioral Health Sciences University in NJ. His current private sector research includes molecular therapeutics in diabetes related neurodegenerative disease. Dr. Frederikse is author of 30+ journal articles as the principal scientist.

Chitra Kasinathan, PhD

Co-founder

Dr. Kasinathan is an Associate Professor in the Department of Oral Biology at the University of Medicine and Dentistry of New Jersey. He received his Doctorate Degree at the Postgraduate Institute of Medical Education and Research in Chandigarh, India. He completed his postdoctoral training in the Department of Physiology and Biophysics at Mount Sinai School of Medicine in New York before joining the Department of Oral Biology at New Jersey Dental School.

Frank Knuettel II

Financial Advisor

Frank Knuettel II is a strong operational and strategic CFO with 25 years of management experience in early stage and micro- and small-cap public companies. He has raised approximately $300 million in venture equity and debt, lines of credit, public equity offerings, convertible debt, PIPEs, bridge loans and other instruments. In addition, he has managed in excess of 15 mergers and acquisitions transactions of companies and / or divisions as both buyer and seller. Mr. Knuettel received his BA with honors in Economics from Tufts University and holds an MBA in Finance and Entrepreneurial Management from The Wharton School at the University of Pennsylvania.

Advisory Board Members

Sean C Martin

Advisor Board, Capital Markets

Sean Martin is CEO and founder of SCM Capital LLC which is a private equity/venture arm that invests in early stage companies, across a diverse realm of businesses,  including Biotechnology, technology, healthcare, satellite technologies, media and special situations. Sean sits on the boards of several private companies as he grooms them for the public markets. SCM has advised several public offerings. His firm advises companies with key personnel hires, Listing mechanics, capital raising and structure.  He brings in a broad knowledge of capital markets from his history. During his twenty five year investment career,  Sean has worked for Paine Webber, UBS, Shearson Lehman Brothers, and Vfinance among others, while building his experience with key investment structures and investment opportunities growth.

Hans Christinger

Advisory Board, Business

Hans is a dedicated leader, innovator and advocate in the rare disease community with over 25 years of experience in the biopharmaceutical industry. At Ovid, Hans establishes and manages global strategic partnerships to rapidly bring potential therapeutics to patients and families affected by rare, neurological disorders, such as Ovid’s relationships with Takeda and Lundbeck. Hans is driven by hope and passion to increase awareness and advance a scientific understanding for members of the rare disease community. Hans plays a critical role in bringing together multiple stakeholders to efficiently address the unmet therapeutic needs within rare and neglected disease communities. Hans has led and executed numerous transactions for Ovid, Ophthotech, Abbott, Roche and Vertex. Having been based both in the US and abroad, he established and led teams to enable global, regional and local transactions across more than 30 countries in emerging and developed markets. Hans is an active board member and advisor to the KIF1A Foundation, NYBIO and several early-stage biotechnology companies. Hans began his career as a bench scientist at Genentech where he authored 15 structural biology related peer-reviewed papers. He earned a Master of Business Administration from Babson College, a Master of Science in Chemistry from San Francisco State University and a Bachelor of Science in Biochemistry from the University of Vermont.

Joseph Schariter

Advisory Board, Science

Joseph Schariter is a chemist with 12 years of experience in Lipid nanoparticle formulation and characterization.  He is recognized for analytical technology evaluation, mentorship, and solving of complex analytical problems.

Joe started his career at Merck where he worked in a specialty analytical group that supported multiple functional areas including manufacturing, safety assessment, and drug metabolism.   He moved to HCV developmental candidates which used more complex formulations ranging from liquid filed capsules to spray dried formulations.  He then developed a passion for complex formulations and biopharmaceutical products, and moved to the siRNA Therapeutics division where he performed chemical and physical characterization of the lipid nanoparticle-based drug delivery system.

Joe joined Moderna Therapeutics in 2014 where he currently oversees the Process Characterization group within LNP Process Development.  In this role, his team focuses on process understanding using heightened characterization with a diverse set of tools.  With these techniques, they help guide process development decisions, scale-up activities, and technology transfer.  His group’s work has led to several patents in the RNA formulation and process space and helped establish the current Vaccine manufacturing platform used to produce the COVID-19 vaccine.

Joe holds a Master’s degree in chemistry from Lehigh University and a Bachelor’s degree in Biochemistry from Lafayette College. He lives in the Boston area with his family and Labrador retriever.

Updates

Update

June 2021

Contact

If you are interested in receiving more information about Sanatio or would like someone to contact you, please use the form to the right or contact us at:

In order to process your registration, we ask you to provide the following information. Please note that all fields marked with an asterisk (*) are required.

Thank you for your message. It has been sent.
There was an error trying to send your message. Please try again later.